Loading people...
Karen Wagner is a General Partner at Ysios Capital based in Switzerland, where she focuses on therapeutic investments in the biotechnology and pharmaceutical sectors. She began her career as a management consultant in the global healthcare practice at McKinsey & Company before transitioning to corporate roles, including Director of Business Development at Ingenium Pharmaceuticals. Wagner later worked at Glycart Biotechnology, which was acquired by F. Hoffmann-La Roche in 2005, and subsequently served as a Global Alliance Director for Roche. Bringing over 25 years of industry experience to her venture capital role, she currently holds board seats at six companies, including Cytoki Pharma and Vivet Therapeutics, and previously directed Kala Pharmaceuticals and Galecto. She holds a doctorate in cell biology from the University of Konstanz and leverages her scientific background to scale early-stage life sciences enterprises.
Karen Wagner stands as a prominent figure in the European life sciences venture capital landscape, serving as a General Partner at Ysios Capital. Her role is pivotal in shaping the future of healthcare by identifying and investing in groundbreaking companies that promise to deliver significant medical advancements. Ysios Capital is renowned for its strategic focus on the life sciences sector, and Karen's contributions are central to its mission of transforming scientific discoveries into tangible patient benefits.
As a General Partner, Karen Wagner is deeply involved in all facets of the investment process, from initial deal sourcing and due diligence to portfolio management and strategic guidance. Her investment focus areas primarily revolve around cutting-edge biotechnology and medical technology. This includes therapeutics, diagnostics, medical devices, and digital health solutions that address unmet medical needs. She is particularly interested in companies that demonstrate strong scientific foundations, innovative intellectual property, and clear pathways to market, aiming to back ventures with the potential for significant impact and robust returns.
Karen's career background in the life sciences and investment sectors provides her with a unique perspective and a profound understanding of the complexities inherent in developing and commercializing healthcare innovations. While specific details of her early career are not publicly detailed, her ascent to General Partner at a firm like Ysios Capital underscores a career marked by strategic acumen, a keen eye for scientific potential, and a proven ability to navigate the intricate world of venture capital. Her experience likely encompasses a blend of scientific, operational, and financial roles, equipping her with the comprehensive skill set required to mentor and grow early-stage companies.
Throughout her tenure at Ysios Capital, Karen has been instrumental in the firm's success, contributing to a portfolio that includes some of Europe's most promising life sciences ventures. While specific notable investments are often confidential or attributed to the firm as a whole, her involvement ensures that Ysios Capital continues to back companies poised to make a substantial difference in patient care. She is known for her collaborative approach, working closely with founders and management teams to provide not just capital, but also strategic insights, operational support, and access to a vast network of industry experts. Her dedication to fostering innovation and her commitment to advancing medical science make Karen Wagner a key driver in the life sciences investment community.
Karen Wagner is a General Partner at Ysios Capital, a leading European venture capital firm specializing in life sciences investments.
Karen Wagner primarily invests in groundbreaking companies within the life sciences sector, focusing on biotechnology, medical technology, therapeutics, diagnostics, and digital health solutions.
Karen Wagner works at Ysios Capital, a prominent European venture capital firm dedicated to investing in innovative life sciences companies.
